Circulating micrornas in serum of human k-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas

Pancreas

Volumn 41, Issue 7, 2012, Pages 1013-1018

  Yabushita, Setsuko ^a   Fukamachi, Katsumi ^b   Tanaka, Hajime ^c   Sumida, Kayo ^a   Deguchi, Yoshihito ^a   Sukata, Tokuo ^a   Kawamura, Satoshi ^a   Uwagawa, Satoshi ^a   Suzui, Masumi ^b   Tsuda, Hiroyuki ^d  

^a SUMITOMO CHEMICAL CO LTD   (Japan)

^b Departments of Molecular Toxicology   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

animal model; biomarker; circulating miRNA; pancreatic cancer; transgenic rat

Indexed keywords

K RAS PROTEIN; MICRORNA; MICRORNA 155; MICRORNA 18A; MICRORNA 203; MICRORNA 21; MICRORNA 210; MICRORNA 30B; MICRORNA 369; MICRORNA 376A; MICRORNA 541; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; MALE; MICROARRAY ANALYSIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SERODIAGNOSIS; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOMA, PANCREATIC DUCTAL; GENES, RAS; HUMANS; MALE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; RATS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84865866510     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31824ac3a5     Document Type: Article

References (27)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Akdogan M, Sasmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2001;87:337-339.
3. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164-169.
4. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. 1998;35:364-370.
5. Chang TC, Mendell JT. MicroRNAS in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet. 2007;8:215-239.
6. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-355.
7. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046-1054.
8. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. J Am Med Assoc. 2007;297:1901-1908.
9. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 2008;54:1716-1724.
10. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26:4442-4452.
11. Zhang Y, Li M, Wang H, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009;33:698-709.
12. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126:73-80.
13. Ikenaga N, Ohuchida K, Mizumoto K, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:3120-3128.
14. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002;48:1647-1653.
15. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008;3:e3148.
16. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106:4402-4407.
17. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
18. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prevention Research (Philadelphia, PA). 2009;2:807-813.
19. Ueda S, Fukamachi K, Matsuoka Y, et al. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis. 2006;27:2497-2510.
20. Tanaka H, Fukamachi K, Futakuchi M, et al. Mature acinar cells are refractory to carcinoma development by targeted activation of ras oncogene in adult rats. Cancer Sci. 2010;101:341-346.
21. Fukamachi K, Tanaka H, Hagiwara Y, et al. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. Biochem Biophys Res Commun. 2009;390:636-641.
22. Fukushima T, Hamada Y, Yamada H, et al. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachlorideVregulating role of micro-RNA for RNA expression. J Toxicol Sci. 2007;32:401-409.
23. Davis-Dusenbery BN, Hata A. MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes and Cancer. 2010;1:1100-1114.
24. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by mir-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007;104:16170-16175.
25. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425-436.
26. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13-21.
27. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226-230.